Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

What factors influence the success or failure of immunotherapy treatment in patients with advanced bladder cancer? Why do ...

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

Mayo Clinic researchers say because ovarian cancer has limited symptoms, it can go undetected until it has spread. At a later ...

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

An ‘all clear’ at the end of treatment doesn’t necessarily mean the end of cancer. But new UK research aims to eliminate the ...

The Global Cancer Immunotherapy Market achieved a valuation of $121.2 Billion in 2023 and is anticipated to exceed $245.37 ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...